Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	701 people 4 RCTs in this analysis	Mean difference in Positive and Negative Syndrome Scale (PANSS) positive symptom subscore with amisulpride (100–1000 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	Mean difference +0.66 95% CI –0.56 to +1.88		Not significant
Systematic review	701 people 4 RCTs in this analysis	Mean difference in PANSS negative symptom subscore with amisulpride (100–1000 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	Mean difference +0.21 95% CI –0.69 to +1.10		Not significant
RCT	80 people	Scale for the Assessment of Positive Symptoms (SAPS) score at baseline 4 to 12 weeks with amisulpride (100–800 mg/day) with olanzapine (10–20 mg/day) Absolute results not reported	Significant improvement in both groups from baseline to 12 weeks (21.3, 95% CI 16.54 to 24.13 with amisulpride v 31.4, 95% CI 27.14 to 35.70 with olanzapine) The RCT reported that the scores between groups were not significantly different at baseline to study end; no further data reported		Not significant
RCT	80 people	Scale for the Assessment of Negative Symptoms (SANS) score at baseline 4 to 12 weeks with amisulpride (100–800 mg/day) with olanzapine (10–20 mg/day) Absolute results not reported	Significant improvement in both groups from baseline to 12 weeks (25.7, 95% CI 22.22 to 29.21 with amisulpride v 26.3, 95% CI 23.6 to 28.97 with olanzapine) The RCT reported that the scores between groups were not significantly different at baseline to study end; no further data reported		Not significant